Lilly/Isis Affinitak development dropped
Executive Summary
Isis "will not invest further in the development of Affinitak," firm says following failure of second pivotal non-small cell lung cancer trial conducted by partner Lilly. Study investigated the antisense inhibitor in combination with Lilly's Gemzar (gemcitabine) and cisplatin; trial results were to determine fate of drug after failure of first Phase III trial in combination with paclitaxel and carboplatin (1"The Pink Sheet" March 24, 2003, p. 29)...
You may also be interested in...
Lilly/Isis Affinitak Pivotal Trial Fails: Future Rests On Second Phase III Study
Lilly will await results from a second Phase III Affinitak study before making a final decision regarding its future role in developing Isis' antisense agent for non-small cell lung cancer
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.